Enterprise Value

1.288B

Cash

561.5M

Avg Qtr Burn

-53.02M

Short % of Float

10.16%

Insider Ownership

1.29%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FILSPARI (Sparsentan) Details
Kidney disease, IgA nephropathy

Approved

Quarterly sales

Approved

Quarterly sales

Phase 3

Data readout

FILSPARI (Sparsentan) Details
IgA nephropathy, Kidney disease

Phase 3

Data readout

Sparsentan Details
Kidney disease, Focal segmental glomerulosclerosis

Phase 3

Update

Phase 3

Initiation